These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14674909)

  • 1. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.
    Kulczycki A; Nelson M; Eisen A; Heffernan M
    Br J Dermatol; 2003 Dec; 149(6):1276-81. PubMed ID: 14674909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg).
    Lister RK; Jolles S; Whittaker S; Black C; Forgacs I; Cramp M; Potter M; Rustin MH
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):403-8. PubMed ID: 10901735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of scleromyxoedema with hydroxychloroquine.
    Terheyden P; Becker JC; Lurz C; Kahaly GJ; Bröcker EB
    J Dtsch Dermatol Ges; 2003 Jan; 1(1):30-5. PubMed ID: 16285290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.
    Shergill B; Orteu CH; McBride SR; Rustin MH
    Br J Dermatol; 2005 Sep; 153(3):650-2. PubMed ID: 16120159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Necrobiotic xanthogranuloma with scleroatrophic lichen associated with paraproteinemia].
    Juárez Y; España S; Lueiro M; Fernández-Díaz ML; Bal F
    Actas Dermosifiliogr; 2006 Nov; 97(9):603-8. PubMed ID: 17173768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Internal disease findings in Arndt-Gottron scleromyxedema].
    Lang E; Goos M
    Dtsch Med Wochenschr; 1986 May; 111(21):820-3. PubMed ID: 3084193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulins control scleromyxoedema.
    Righi A; Schiavon F; Jablonska S; Doria A; Blasczyk M; Rondinone R; Todesco S; Matucci Cerinic M
    Ann Rheum Dis; 2002 Jan; 61(1):59-61. PubMed ID: 11779761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extragenital lichen sclerosus et atrophicus: about a case].
    Zemmez Y; Amraoui ME; Bouhamidi A; Azhari JE; Ismaili N; Benzekri L; Meziane M; Hassam B; Senouci K
    Pan Afr Med J; 2016; 25():190. PubMed ID: 28292152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
    Sillard L; Passeron T; Cardot-Leccia N; Perrin C; Lacour JP; Ortonne JP
    Ann Dermatol Venereol; 2010 Jan; 137(1):48-52. PubMed ID: 20110069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
    Körber A; Franckson T; Grabbe S; Dissemond J
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
    [No Abstract]   [Full Text] [Related]  

  • 11. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
    Manousaridis I; Loeser C; Goerdt S; Hassel JC
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
    Wang SS; Chen QY; Xiang LH
    Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretibial myxedema and high-dose intravenous immunoglobulin treatment.
    Antonelli A; Navarranne A; Palla R; Alberti B; Saracino A; Mestre C; Roger P; Agostini S; Baschieri L
    Thyroid; 1994; 4(4):399-408. PubMed ID: 7711502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUVA treatment of scleromyxoedema.
    Farr PM; Ive FA
    Br J Dermatol; 1984 Mar; 110(3):347-50. PubMed ID: 6696849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
    Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
    Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
    Laimer M; Namberger K; Massone C; Koller J; Emberger M; Pleyer L; Hintner H; Greil R
    Acta Derm Venereol; 2009 Nov; 89(6):631-5. PubMed ID: 19997697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.
    Wojas-Pelc A; Błaszczyk M; Glińska M; Jabłońska S
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):462-5. PubMed ID: 15987294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic involvement in scleredema of Buschke associated with IgG-kappa paraproteinaemia.
    Basarab T; Burrows NP; Munn SE; Russell Jones R
    Br J Dermatol; 1997 Jun; 136(6):939-42. PubMed ID: 9217831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report.
    Arginelli F; Rongioletti F; Girolomoni G; Pellacani G; Guardoli D; Conti A
    J Int Med Res; 2016 Sep; 44(1 suppl):109-112. PubMed ID: 27683152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a.
    Kumar N; Rodriguez M
    Mult Scler; 2004 Feb; 10(1):85-6. PubMed ID: 14760958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.